A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Prior treatment

• Have a self-reported change in body weight \>5 kilogram (kg) (11 pounds) within 90 days before screening.
• Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin
• Have a prior or planned surgical treatment for obesity

Other illness

• Have Type 1 Diabetes (T1D)
• Have acute or chronic hepatitis
• Have a history of malignant disease within 5 years before screening.

• Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²)
• Have either
  • no T2D with an HbA1c \< 6.5% or
  • have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.
• Have been diagnosed with chronic kidney disease (CKD).